Infigratinib is a weak inhibitor of the FGFR3-N540K mutant associated with hypochondroplasia

• Authors: URSACHI Vlad-Constantin; FEKETOVÁ Zuzana; CZYREK Aleksandra Anna; ŠESTÁKOVÁ Klára; SVOZILOVÁ Kateřina; RICO LLANOS Gustavo; KREJČÍ Pavel
• Year of publication: 2026
• Type: Peer-reviewed scientific article
• Magazine / Source: Journal of bone and mineral research
• web: https://academic.oup.com/jbmr/advance-article/doi/10.1093/jbmr/zjag017/8440975
• Doi: https://doi.org/10.1093/jbmr/zjag017
• Keywords: achondroplasia; hypochondroplasia; ACH; HCH; FGFR3; N540K; infigratinib; treatment; efficacy

Related projects

• Prenatal treatment of achondroplasia
• Affordable and accessible: Redefining the future of achondroplasia treatment with repurposed FGFR inhibitors